Jci_page_head_homepage_01 Jci_page_head_homepage_02
Christofer Samuelsson, Jürgen Hausmann, Henning Lauterbach, Michaela Schmidt, Shizuo Akira, Hermann Wagner, Paul Chaplin, Mark Suter, Meredith O’Keeffe, Hubertus Hochrein
Published in Volume 118, Issue 5
J Clin Invest. 2008; 118(5):1776–1784 doi:10.1172/JCI33940
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 9
MVA therapeutically protects TLR9-deficient mice if applied after infection with a lethal dose of ECTV.

TLR9-deficient mice were infected intranasally with 100 TCID50 ECTV. After the indicated times of 24 hours (A) or 48 hours or 72 hours (B), the ECTV-infected mice were inoculated intranasally with 1 × 108 TCID50 of MVA (black symbols) or without (gray squares), and survival was monitored for 4 weeks. The experiments were performed with the indicated numbers of mice, and data show the cumulative results of 3 individual experiments (A) or 1 experiment (B). Note that the 9 control mice in A include the 3 control mice in B.